Duvakitug

DB19444InvestigationalProtein Based Therapies

Duvakitug is under investigation in clinical trial NCT05668013 (A Study to Evaluate the Long-term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease).

Mechanism: Pharmacologically active on Tumor necrosis factor ligand superfamily member 15
Curator reviewed
Also known as: Du vakitug · gamma1 heavy chain Homo sapiens (1-448) [VH (Homo sapiens IGHV1-8*01 (92.9%) -(IGHD) -IGHJ4*01 (92.9%),CDR-IMGT [8.8.12] (26-33.51-58.97-108)) (1-119)-Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, CH3 D12,L14 (CH1 K120 (216) (120-217), hinge 1-15 (218- · Immunoglobulin G1 [de-449-lysine], anti-(human tumor necrosis factor superfamily protein TNFSF15) (human monoclonal TEV-48574 γ1-chain), disulfide with human monoclonal TEV-48574 λ-chain, dimer
Code names: SAR447189 · TEV-48574

Resolves to

Compound

UNIIB2I7YTE4ZACAS2750005-84-4

Targets

O95150TNFSF15

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Duvakitug, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account